Citadel Advisors’s Epizyme, Inc EPZM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-48,500
| Closed | -$71K | – | 14246 |
|
|
2022
Q2 | $71K | Buy |
48,500
+22,400
| +86% | +$16.5K | ﹤0.01% | 11699 |
|
|
2022
Q1 | $30K | Sell |
26,100
-8,700
| -25% | -$14.2K | ﹤0.01% | 13116 |
|
|
2021
Q4 | $87K | Buy |
34,800
+15,200
| +78% | +$59.7K | ﹤0.01% | 12854 |
|
|
2021
Q3 | $100K | Sell |
19,600
-26,500
| -57% | -$161K | ﹤0.01% | 12874 |
|
|
2021
Q2 | $383K | Sell |
46,100
-1,000
| -2% | -$8.43K | ﹤0.01% | 10676 |
|
|
2021
Q1 | $410K | Buy |
47,100
+15,600
| +50% | +$161K | ﹤0.01% | 10121 |
|
|
2020
Q4 | $342K | Sell |
31,500
-1,200
| -4% | -$14.8K | ﹤0.01% | 8846 |
|
|
2020
Q3 | $390K | Sell |
32,700
-8,200
| -20% | -$110K | ﹤0.01% | 7711 |
|
|
2020
Q2 | $657K | Sell |
40,900
-7,400
| -15% | -$129K | ﹤0.01% | 6581 |
|
|
2020
Q1 | $749K | Buy |
48,300
+7,100
| +17% | +$152K | ﹤0.01% | 5816 |
|
|
2019
Q4 | $1.01M | Buy |
+41,200
| New | +$612K | ﹤0.01% | 5553 |
|
|
2019
Q3 | – | Sell |
-14,500
| Closed | -$182K | – | 9973 |
|
|
2019
Q2 | $182K | Buy |
14,500
+2,000
| +16% | +$25.7K | ﹤0.01% | 8254 |
|
|
2019
Q1 | $155K | Buy |
+12,500
| New | +$140K | ﹤0.01% | 8373 |
|
|
2016
Q1 | – | Sell |
-1,500
| Closed | -$24K | – | 8352 |
|
|
2015
Q4 | $24K | Sell |
1,500
-1,200
| -44% | -$17.8K | ﹤0.01% | 7810 |
|
|
2015
Q3 | $35K | Sell |
2,700
-5,100
| -65% | -$103K | ﹤0.01% | 7820 |
|
|
2015
Q2 | $187K | Buy |
7,800
+4,600
| +144% | +$88.5K | ﹤0.01% | 6414 |
|
|
2015
Q1 | $60K | Buy |
3,200
+2,500
| +357% | +$51.6K | ﹤0.01% | 7270 |
|
|
2014
Q4 | $13K | Sell |
700
-1,000
| -59% | -$23.4K | ﹤0.01% | 8050 |
|
|
2014
Q3 | $46K | Buy |
+1,700
| New | +$52.8K | ﹤0.01% | 6949 |
|
Other funds holding EPZM
Citadel Advisors's EPZM Position: Q3 2022 in Review
Citadel Advisors sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 691,458 shares — an estimated $1.02M sold.
Citadel Advisors first reported a position in EPZM in Q2 2014 and held it in 26 quarters. The position peaked at $11M in Q2 2018. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.
- Citadel Advisors reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
- Citadel Advisors sold 691,458 Epizyme, Inc shares in Q3 2022, an estimated $1.02M.
- Citadel Advisors first reported a position in Epizyme, Inc in Q2 2014 and held it in 26 quarters.
- Citadel Advisors's Epizyme, Inc position peaked at $11M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.
Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.